This trial is being done to find out if elezanumab is safe and to see if it improves motor function in people with acute cervical SCI.
1 Primary · 2 Secondary · Reporting Duration: 52 Weeks
Experimental Treatment
Non-Treatment Group
54 Total Participants · 2 Treatment Groups
Primary Treatment: Elezanumab · Has Placebo Group · Phase 2
Age 18 - 75 · All Participants · 4 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Florida | 100.0% |
18 - 65 | 100.0% |
Shepherd Center, Inc /ID# 230370 | 100.0% |
Did not meet criteria | 100.0% |